Zogenix (ZGNX) Signs Joint Marketing and Technology Development Agreement with Battelle to Advance Development of DosePro® Drug Delivery Technology
Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that they have signed a non-binding letter of intent for an exclusive co-marketing and technology development option agreement with Battelle to advance the development and commercialization of Zogenix's DosePro® drug. Battelle, one of the world's largest independent research and development organizations, will work with Zogenix to offer DosePro needle-free drug delivery technology to pharmaceutical and biotechnology firms for new commercial out-licensing opportunities. Zogenix's DosePro patented technology, which has United States and Europe regulatory approvals, enables needle-free medication delivery under…